LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Golan, Talia, Geva, Ravit, Richards, Donald, Madhusudan, Srinivasan, Lin, Boris Kin, Wang, Haofei Tiffany, Walgren, Richard A., Stemmer, Salomon M.
Published in Journal of cachexia, sarcopenia and muscle (01.10.2018)
Published in Journal of cachexia, sarcopenia and muscle (01.10.2018)
Get full text
Journal Article
Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN)
Price, Gregory L, Davis, Keith L, Karve, Sudeep, Pohl, Gerhardt, Walgren, Richard A
Published in PloS one (11.03.2014)
Published in PloS one (11.03.2014)
Get full text
Journal Article
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
Hess, Lisa M., Chen, Yongmei, Abada, Paolo B., Konig, Heiko, Walgren, Richard A.
Published in Advances in Hematology (28.12.2022)
Published in Advances in Hematology (28.12.2022)
Get full text
Journal Article
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
Konicek, Bruce W, Capen, Andrew R, Credille, Kelly M, Ebert, Philip J, Falcon, Beverly L, Heady, Gary L, Patel, Bharvin K R, Peek, Victoria L, Stephens, Jennifer R, Stewart, Julie A, Stout, Stephanie L, Timm, David E, Um, Suzane L, Willard, Melinda D, Wulur, Isabella H, Zeng, Yi, Wang, Yong, Walgren, Richard A, Betty Yan, Sau-Chi
Published in Oncotarget (02.03.2018)
Published in Oncotarget (02.03.2018)
Get full text
Journal Article
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis
Graubert, Timothy A, Payton, Michelle A, Shao, Jin, Walgren, Richard A, Monahan, Ryan S, Frater, John L, Walshauser, Mark A, Martin, Mike G, Kasai, Yumi, Walter, Matthew J
Published in PloS one (25.02.2009)
Published in PloS one (25.02.2009)
Get full text
Journal Article
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
Arkenau, Hendrik‐Tobias, Martin‐Liberal, Juan, Calvo, Emiliano, Penel, Nicolas, Krebs, Matthew G., Herbst, Roy S., Walgren, Richard A., Widau, Ryan C., Mi, Gu, Jin, Jin, Ferry, David, Chau, Ian
Published in The oncologist (Dayton, Ohio) (01.12.2018)
Published in The oncologist (Dayton, Ohio) (01.12.2018)
Get full text
Journal Article
Transport of Quercetin and Its Glucosides across Human Intestinal Epithelial Caco-2 Cells
Walgren, Richard A, Walle, U.Kristina, Walle, Thomas
Published in Biochemical pharmacology (15.05.1998)
Published in Biochemical pharmacology (15.05.1998)
Get full text
Journal Article
Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?
Walgren, Richard A, Meucci, Melissa A, McLeod, Howard L
Published in Journal of clinical oncology (10.10.2005)
Published in Journal of clinical oncology (10.10.2005)
Get full text
Journal Article
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Valle, Juan W, Vogel, Arndt, Denlinger, Crystal S, He, Aiwu Ruth, Bai, Li-Yuan, Orlova, Rashida, Van Cutsem, Eric, Adeva, Jorge, Chen, Li-Tzong, Obermannova, Radka, Ettrich, Thomas J, Chen, Jen-Shi, Wasan, Harpreet, Girvan, Allicia C, Zhang, Wei, Liu, Jiangang, Tang, Chunlao, Ebert, Philip J, Aggarwal, Amit, McNeely, Samuel C, Moser, Brian A, Oliveira, Joana M, Carlesi, Roberto, Walgren, Richard A, Oh, Do-Youn
Published in The lancet oncology (01.10.2021)
Published in The lancet oncology (01.10.2021)
Get full text
Journal Article
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Wang, Michael L, Jurczak, Wojciech, Zinzani, Pier Luigi, Eyre, Toby A, Cheah, Chan Y, Ujjani, Chaitra S, Koh, Youngil, Izutsu, Koji, Gerson, James N, Flinn, Ian, Tessoulin, Benoit, Alencar, Alvaro J, Ma, Shuo, Lewis, David, Lech-Maranda, Ewa, Rhodes, Joanna, Patel, Krish, Maddocks, Kami, Lamanna, Nicole, Wang, Yucai, Tam, Constantine S, Munir, Talha, Nagai, Hirokazu, Hernandez-Ilizaliturri, Francisco, Kumar, Anita, Fenske, Timothy S, Seymour, John F, Zelenetz, Andrew D, Nair, Binoj, Tsai, Donald E, Balbas, Minna, Walgren, Richard A, Abada, Paolo, Wang, Chunxiao, Zhao, Junjie, Mato, Anthony R, Shah, Nirav N
Published in Journal of clinical oncology (20.08.2023)
Published in Journal of clinical oncology (20.08.2023)
Get full text
Journal Article
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
Gomez, Eliana B., Ebata, Kevin, Randeria, Hetal S., Rosendahl, Mary S., Cedervall, E. Peder, Morales, Tony H., Hanson, Lauren M., Brown, Nicholas E., Gong, Xueqian, Stephens, Jennifer, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A., Abada, Paolo B., Ballard, Joshua A., Allerston, Charles K., Brandhuber, Barbara J.
Published in Blood (06.07.2023)
Published in Blood (06.07.2023)
Get full text
Journal Article
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study
Eyre, Toby A., Hess, Lisa M., Sugihara, Tomoko, He, Dan, Khanal, Manoj, Pagel, John M., Walgren, Richard A., B. Abada, Paolo, Konig, Heiko, Roeker, Lindsey E., Mato, Anthony
Published in Leukemia & lymphoma (16.04.2023)
Published in Leukemia & lymphoma (16.04.2023)
Get full text
Journal Article
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Petrylak, Daniel P, Tagawa, Scott T, Kohli, Manish, Eisen, Andrea, Canil, Christina, Sridhar, Srikala S, Spira, Alexander, Yu, Evan Y, Burke, John M, Shaffer, David, Pan, Chong-Xian, Kim, Jenny J, Aragon-Ching, Jeanny B, Quinn, David I, Vogelzang, Nicholas J, Tang, Shande, Zhang, Hui, Cavanaugh, Christopher T, Gao, Ling, Kauh, John S, Walgren, Richard A, Chi, Kim N
Published in Journal of clinical oncology (01.05.2016)
Published in Journal of clinical oncology (01.05.2016)
Get full text
Journal Article
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study
Mato, Anthony R., Hess, Lisa M., Chen, Yongmei, Abada, Paolo B., Konig, Heiko, Pagel, John M., Walgren, Richard A.
Published in Clinical lymphoma, myeloma and leukemia (01.01.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.01.2023)
Get full text
Journal Article
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Yan, S. Betty, Um, Suzane L., Peek, Victoria L., Stephens, Jennifer R., Zeng, Wei, Konicek, Bruce W., Liu, Ling, Manro, Jason R., Wacheck, Volker, Walgren, Richard A.
Published in Investigational new drugs (01.08.2018)
Published in Investigational new drugs (01.08.2018)
Get full text
Journal Article
Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
WENJUAN WU, CHEN BI, CREDILLE, Kelly M, MANRO, Jason R, PEEK, Victoria L, DONOHO, Gregory P, LEI YAN, WIJSMAN, John A, YAN, S. Betty, WALGREN, Richard A
Published in Clinical cancer research (15.10.2013)
Published in Clinical cancer research (15.10.2013)
Get full text
Journal Article
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Published in Investigational new drugs (01.08.2013)
Published in Investigational new drugs (01.08.2013)
Get full text
Journal Article
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Wit, Ronald, Powles, Thomas, Castellano, Daniel, Necchi, Andrea, Lee, Jae‐Lyun, Heijden, Michiel S., Matsubara, Nobuaki, Bamias, Aristotelis, Fléchon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Zimmermann, Annamaria H., Long, Amanda, Walgren, Richard A., Gao, Ling, Bell‐McGuinn, Katherine M., Petrylak, Daniel P.
Published in British journal of clinical pharmacology (01.07.2022)
Published in British journal of clinical pharmacology (01.07.2022)
Get full text
Journal Article
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility
Knight, Jeffrey A., Skol, Andrew D., Shinde, Abhijit, Hastings, Darcie, Walgren, Richard A., Shao, Jin, Tennant, Thelma R., Banerjee, Mekhala, Allan, James M., Le Beau, Michelle M., Larson, Richard A., Graubert, Timothy A., Cox, Nancy J., Onel, Kenan
Published in Blood (28.05.2009)
Published in Blood (28.05.2009)
Get full text
Journal Article
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Verstovsek, Srdan, Mesa, Ruben A., Salama, Mohamed E., Li, Li, Pitou, Celine, Nunes, Fabio P., Price, Gregory L., Giles, Jennifer L., D’Souza, Deborah N., Walgren, Richard A., Prchal, Josef T.
Published in Leukemia research (01.10.2017)
Published in Leukemia research (01.10.2017)
Get full text
Journal Article